Novavax phase 3 results. Novavax Inc has announced initial results from its phase 3 clinical trial ...
Novavax phase 3 results. Novavax Inc has announced initial results from its phase 3 clinical trial evaluating its COVID-19–influenza combination vaccine (CIC) and a stand-alone trivalent influenza vaccine candidate (tNIV) in older adults. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025. Feb 2, 2024 路 Developed by University of Oxford and Serum Institute of India, the vaccine contains Novavax’s saponin-based Matrix-M™ adjuvant. com and LinkedIn for more information. ly/3qGPwaH 馃挰50 Feb 27, 2026 路 Opportunities and Catalysts Sanofi Milestone: Sanofi is expected to launch its own Phase 3 trial using Novavax tech in 2026, which would trigger a $125 million milestone payment to Novavax. Sep 22, 2023 路 These responses were compared for the three lots, and for participants with primary series with or without a prior booster dose of the mRNA-1273, BNT162b2, Ad26. Feb 27, 2026 路 Opportunities and Catalysts Sanofi Milestone: Sanofi is expected to launch its own Phase 3 trial using Novavax tech in 2026, which would trigger a $125 million milestone payment to Novavax. (Nasdaq: NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alonetrivalent hemagglutinin nanoparticleseasonal influenza (tNIV) Phase 3 trial that showed both the CIC and flu May 5, 2021 路 In a large, multinational, phase 3 trial evaluating the efficacy of a single dose of the Ad26. S vaccine (Johnson & Johnson/Janssen), efficacy against moderate-to-severe Covid-19 among 6576 Aug 31, 2022 路 On Feb. S, or NVX-CoV2373 COVID-19 vaccines. tbfpigtaabbjfcyahqsfhukyzanxswloeypuahfaefiqializajqs